Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Tuesday that its second quarter revenues rose 168 percent year over year, thanks largely to strong growth in its melanoma and uveal melanoma test volumes.

For the three months ended June 30, the skin cancer test developer reported total revenues of $10.7 million, up from $4.0 million during the same period a year earlier, and beating the average Wall Street analyst estimate of $7.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.